BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-154@catalystbrief.girapphe.com
DTSTAMP:20261118T181558Z
LAST-MODIFIED:20261118T181558Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Janssen Research & Development\, LLC — Icotrokinra [Feb 
 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate the Efficacy an
 d Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologi
 c-naive Participants With Active Psoriatic Arthritis.\nSource: https://cli
 nicaltrials.gov/study/NCT06807424\nhttps://catalystbrief.girapphe.com/e/15
 4?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/154?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
